Raymond James Financial Inc. Takes Position in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)

Raymond James Financial Inc. purchased a new position in shares of Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) in the fourth quarter, HoldingsChannel reports. The fund purchased 306,290 shares of the company’s stock, valued at approximately $2,974,000.

Several other large investors have also added to or reduced their stakes in the company. Flow Traders U.S. LLC purchased a new position in shares of Global X Genomics & Biotechnology ETF during the third quarter worth $936,000. Rockefeller Capital Management L.P. purchased a new position in shares of Global X Genomics & Biotechnology ETF during the 3rd quarter valued at about $205,000. Corrado Advisors LLC lifted its holdings in shares of Global X Genomics & Biotechnology ETF by 17.3% in the 4th quarter. Corrado Advisors LLC now owns 75,323 shares of the company’s stock valued at $731,000 after buying an additional 11,099 shares during the period. Oxinas Partners Wealth Management LLC purchased a new stake in shares of Global X Genomics & Biotechnology ETF in the fourth quarter worth about $103,000. Finally, Sanctuary Advisors LLC acquired a new stake in Global X Genomics & Biotechnology ETF during the fourth quarter worth about $104,000. Hedge funds and other institutional investors own 56.95% of the company’s stock.

Global X Genomics & Biotechnology ETF Trading Down 1.9 %

Shares of GNOM stock opened at $8.35 on Friday. Global X Genomics & Biotechnology ETF has a twelve month low of $8.31 and a twelve month high of $11.88. The stock has a market cap of $58.20 million, a P/E ratio of -3.57 and a beta of 1.03. The stock has a 50 day moving average of $9.44 and a 200 day moving average of $10.15.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.